Accès ouvert
2025
article
OpenAlex
Angel J. Magaña, David Chek Ling Ngo, Kenneth Burgos, Carolina Dominguez Maldonado et autres
Abstract The ongoing antibiotic resistance crisis is one of the most pressing public health challenges. Multidrug-resistant bacterial pathogens are reaching the point where some are becoming untreatable. Consequently, besides discovering novel antibiotics, alternative strategies must be explored to manage the problem. One …
us, ar
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Jan Sklenicka, Tung Tran, Angel J. Magaña, María Soledad Ramirez et autres
Abstract Background The aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6’)-Ib] confers resistance to amikacin and other relevant aminoglycosides in Gram-negatives. To identify small molecule inhibitors of AAC(6’)-Ib that would overcome resistance, we utilized a strategy incorporating mixture-based combinatorial libraries, scaffold ranking, and positional scanning, …
us
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Angel J. Magaña, David Chek Ling Ngo, Kenneth Burgos, Carolina Dominguez Maldonado et autres
The ongoing antibiotic resistance crisis is among the most pressing public health chal-lenges. The rise and dissemination of multidrug-resistant bacterial pathogens is reaching the point when some become untreatable. Consequently, besides discovering novel antibiotics, alternative strategies must be explored to manage the …
us, ar
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jan Sklenicka, Tung Tran, María Soledad Ramirez, Haley M. Donow et autres
Resistance to amikacin and other major aminoglycosides is commonly due to enzymatic acetylation by the aminoglycoside 6′-N-acetyltransferase type I enzyme, of which type Ib [AAC(6′)-Ib] is the most widespread among Gram-negative pathogens. Finding enzymatic inhibitors could be an effective way to overcome …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Jan Sklenicka, Tung Tran, María Soledad Ramirez, Haley M. Donow et autres
Abstract Resistance to amikacin and other major aminoglycosides is commonly due to enzymatic acetylation by aminoglycoside 6′- N -acetyltransferase type I enzyme, of which type Ib [AAC(6′)-Ib] is the most widespread among Gram-negative pathogens. Finding enzymatic inhibitors could be an effective way …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Ophélie d’Udekem d’Acoz, Fong Hue, Tianyi Ye, Louise Wang et autres
ABSTRACT Aminoglycosides are essential components in the available armamentarium to treat bacterial infections. The surge and rapid dissemination of resistance genes strongly reduce their efficiency, compromising public health. Among the multitude of modifying enzymes that confer resistance to aminoglycosides, the aminoglycoside 6′- …
ca, us
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Ophélie d’Udekem d’Acoz, Fong Hue, Tianyi Ye, Louise Wang et autres
Abstract Aminoglycosides are essential components in the available armamentarium to treat bacterial infections. The surge and rapid dissemination of resistance genes strongly reduce their efficiency, compromising public health. Among the multitude of modifying enzymes that confer resistance to aminoglycosides, the aminoglycoside acetyltransferase …
ca, us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Minh C. Tran, Douglas C. Crockett, Richard Bruce, Sophie Taylor et autres
gb
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
David Chek Ling Ngo, Angel J. Magaña, Tung Tran, Jan Sklenicka et autres
Plazomicin is a recent U.S. Food and Drug Administration (FDA)-approved semisynthetic aminoglycoside. Its structure consists of a sisomicin scaffold modified by adding a 2(S)-hydroxy aminobutyryl group at the N1 position and a hydroxyethyl substituent at the 6′ position. These substitutions produced a …
us
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Craig Reeves, Jesus Magallón, Kenneth Rocha, Tung Tran et autres
Clinical resistance to amikacin and other aminoglycosides is usually due to the enzymatic acetylation of the antimicrobial molecule. A ubiquitous resistance enzyme among Gram-negatives is the aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6′)-Ib], which catalyzes acetylation using acetyl-CoA as a donor substrate. Therapies that …
us
(code pays fourni par la source)
2020
article
OpenAlex
Craig Reeves, Jesus Magallón, Kenneth Rocha, Tung Tran et autres
Clinical resistance to amikacin and other aminoglycosides is usually due to the enzymatic acetylation of the antimicrobial molecule. A ubiquitous resistance enzyme among Gram-negatives is the aminoglycoside 6′-N-acetyltransferase type Ib [AAC(6′)-Ib], which catalyzes acetylation using acetyl-CoA as a donor substrate. Therapies that …
us
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Jesus Magallón, Kevin Chiem, Tung Tran, María Soledad Ramirez et autres
Gram-negative pathogens resistant to amikacin and other aminoglycosides of clinical relevance usually harbor the 6'-N-acetyltransferase type Ib [AAC(6')-Ib], an enzyme that catalyzes inactivation of the antibiotic by acetylation using acetyl-CoA as donor substrate. Inhibition of the acetylating reaction could be a way …
us
(code pays fourni par la source)